Skip to main content
. 2019 Dec 12;12(1):1690959. doi: 10.1080/19420862.2019.1690959

Figure 2.

Figure 2.

CDC activity of bivalent anti-EGFR IgGs and their respective monovalent bispecific DuetMabs. (a–c) CDC activity of QD6 IgG and QD6/NMGC DuetMab against MDA-MB-468 (a), HCC827 (b), and A431 (c) cells at 10%, 10%, and 5% serum concentrations. (d–f) CDC activity of GA201 IgG, GA201/NMGC DuetMab against MDA-MB-468 (d), HCC827 (e), and A431 (f) cells at the corresponding serum concentrations as for the QD6 antibody set. (g–i) CDC activity of cetuximab IgG, cetuximab/NMGC DuetMab against MDA-MB-468 (g), HCC827 (h), and A431 (i) cells at the corresponding serum concentrations as for the QD6 antibody set. NMGC was used as an isotype control. Each point represents the mean values of triplicate wells, and the standard error of the mean is represented by error bars. See Table 2 for statistical analysis and P values.